Dr. Andreas Meyer-Lindenberg as New Editor-in-Chief of journal: European Neuropsychopharmacology

Primary tabs

Dr. Andreas Meyer-Lindenberg as New Editor-in-Chief of journal: European Neuropsychopharmacology

tweet me:
#Elsevier #ENP Dr. Andreas Meyer-Lindenberg as New Editor-in-Chief of journal: European Neuropsychopharmacology: http://bit.ly/YUsuPH
Thursday, September 18, 2014 - 9:00am

CONTENT: Press Release

Utrecht, the Netherlands, September 18, 2014 /3BL Media/ -  The European College of Neuropsychopharmacology  is pleased to announce Professor Andreas Meyer-Lindenberg, MD, Director of the Central Institute of Mental Health in Mannheim, and Chair of Psychiatry at the University of Heidelberg, as the new editor-in-chief of European Neuropsychopharmacology (ENP), the official journal of the European College of Neuropsychopharmacology (ECNP). Meyer-Lindenberg was jointly appointed by the College and the journal’s publisher Elsevier, for a three year term. He takes over from Professor Michael Davidson, MD, Chairman of Psychiatry at Tel Aviv University, who led the journal for the maximum term of six years and presided over a strong increase in the journals impact and reach.

The European College of Neuropsychopharmacology (ECNP) is Europe’s leading interdisciplinary forum for the science and treatment of disorders of the brain. In its mission to promote the communication and cross- fertilisation of high-quality experimental and clinical research across the field of neuroscience, the journal ENP plays a critical role.

Meyer-Lindenberg’s research interests focus on the development of novel treatments for severe psychiatric disorders, especially schizophrenia, through an application of multimodal neuroimaging, genetics and environmental science to characterize brain circuits underlying the risk for mental illness and cognitive dysfunction. He is a member of the Executive Board of the ECNP and has been an Associate Editor of the journal for four years prior to his appointment.

“There has rarely been a time in which so many scientific advances in neuroscience are available to advance the treatment and prevention of neuropsychiatric disorders,” said Professor Meyer-Lindenberg. “I am excited to work with an expert team of editors to consolidate and expand the position of ENP as a premier journal for the best in translational research in our field”.

Guy Goodwin, FMedSci, President of ECNP, said, “We are very grateful of Professor Michael Davidson for the high standards of collegiality and quality he has set during his outstanding tenure as editor. He has worked with closely with Andreas to ensure a natural and seamless transition and Andreas is the ideal person to lead ENP in the next phase of its evolution, at a time of growing optimism in applied neuroscience.”

”We congratulate Professor Meyer-Lindenberg on his new role with the journal, and look forward to working closely with him as the journal develops and grows,” said Herb Niemirow, Publisher at Elsevier.


About ECNP
The European College of Neuropsychopharmacology (ECNP) is an independent scientific association dedicated to translating advances in the understanding of brain function and human behaviour into better treatments and enhanced public health. ECNP organises a wide range of scientific and educational activities, programmes and events across Europe, promoting exchange of high-quality experimental and clinical research and fostering young scientists and clinicians in the field.  The annual ECNP Congress attracts around 4,000-7,000 scientists and clinicians from across the world to discuss the latest advances in brain research in Europe’s largest meeting on brain science. http://www.ecnp.eu/about-ecnp.aspx

About European Neuropsychopharmacology
European Neuropsychopharmacology is the official journal of the European College of Neuropsychopharmacology (ECNP). It publishes articles and commentary on neuroscientific advances relevant for the treatment of neuropsychiatric disorders and thus advances the college’s mission to translate new knowledge on fundamental disease mechanisms into new medicines and clinical applications. The journal belongs to the top twenty worldwide in psychiatry and currently has an impact factor of 5.395.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Parkhill
ECNP Press Officer
+44 131 208 3008

Natalie Hill-Krasniqi
+44 20 7424 4404

Keywords: Health | Dr. Andreas Meyer-Lindenberg | ECNP | ENP | Education | Elsevier | European Neuropsychopharmacology | Health | Pharma News, Research & Solutions

CONTENT: Press Release